Top Markets
Coin of the day
Satsuma Pharmaceuticals, Inc. Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc.

STSA
Rank in Stocks #29910
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.
Share Price
$1.10
Last synced: 2023-06-07
Market Cap
$19.12M
Change (1 day)
-0.90%
Change (1 year)
0.00%
Country
US
Trade Satsuma Pharmaceuticals, Inc. (STSA)

Category

Operating Margin for Satsuma Pharmaceuticals, Inc. (STSA)
Operating Margin as of 2026 TTM: 0.00%
According to Satsuma Pharmaceuticals, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Satsuma Pharmaceuticals, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
28.81% -
NL
25.72% -
AU
0.00% -
CH
0.00% -
KR
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.